Retatrutide: A New Obesity Drug Showing Substantial Weight Loss Results in Patients with Obesity or Type 2 Diabetes

According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 42.4% of Americans have obesity. As you grapple with these scary statistics, the physical consequences of obesity are well known, ranging from type 2 diabetes, heart disease, breathing problems, hypertension, certain cancer types, and joint issues. Moreover, unhealthy weight can take a toll on your mental and emotional health.

EndoSlim Clinic NY of Atlantic Gastroenterology in Brooklyn, New York, understands the “visible and invisible” burden shouldered by patients battling obesity. Dr. Alexander Shapsis — a Board-Certified gastroenterologist — wants to keep you informed about developments in medicine regarding obesity. Have you heard about retatrutide? If not, we’ll shed light on this new weight loss drug from Eli Lilly that has shown more promising results than any drug in its class. 

What is retatrutide?

Retatrutide is in the same class as other weight loss drugs like Mounjaro, Ozempic, and Wegovy. However, what sets it apart from other obesity medications is that it targets three hunger-reducing hormones. Wegovy only targets one hunger-controlling hormone called GLP-1, while Mounjaro targets GLP-1 and GIP. Retatrutide takes it a notch higher by targeting three hunger-regulating hormones: GIP, GLP-1, and glucagon receptor.

Retatrutide’s “triple G” effect could make this medication more potent than its rivals. This injectable drug showed incredible results during the experimental stage, helping patients lose up to 24% of weight (almost 60 pounds) in a year. These are the highest results ever seen in anti-obesity medication to date. 

What about side effects? 

Like other obesity-related medications, retatrutide’s side effects are mostly gastrointestinal, including nausea, vomiting, constipation, and diarrhea.

How does retatrutide work? 

Like Mounjaro or Wegovy, retatrutide is a weekly injection that decreases your appetite by mimicking certain hormones in the gut. Retatrutide mimics GLP-1 and GIP but also targets another hormone — glucagon— involved in hunger regulation. Glucagon controls lipid and glucose metabolism, which plays a significant role in weight loss.

Although the clinical tests show encouraging results, it can take up to a few more years before retatrutide is approved by the Food and Drug Administration (FDA) since phase three trials may take longer. Eli Lilly hopes to look beyond retatrutide’s weight reduction potential during this triumph stage. This phase will evaluate retatrutide’s safety and efficacy in treating obesity and its complications comprehensively.

Learn more about retatrutide today!

Want to learn more about the new kid on the block — retatrutide? 

Please call 718 521-2840 to talk to Dr. Alexander Shapsis about everything you need to know about obesity management.